Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA<sub>1c</sub> Testing at Community Pharmacies in Japan.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29686159.
- Also identified by DOI 10.2337/dc17-1307.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A new opportunistic community-based strategy was launched in Japan in April 2014 to detect lifestyle-related diseases, including diabetes, by creating Specimen Measurement Offices (SMOs). SMOs offer walk-in fingertip HbA<sub>1c</sub> testing. This article aimed to assess the value-for-money of HbA<sub>1c</sub> testing services at SMOs by conducting a cost-effectiveness analysis. We compared two scenarios: <i>1</i>) status quo, defined as HbA<sub>1c</sub> testing that is available only through conventional screening, and <i>2</i>) HbA<sub>1c</sub> testing available at SMOs as a complement to the status quo scenario. The model consisted of a screening module with a decision tree and a disease progression module with a Markov model. We calculated incremental cost-effectiveness ratios (i.e., cost per quality-adjusted life-years [QALYs]) over the lifetime analytic horizon as the primary end point of the cost-effectiveness analysis. In this model, we assumed the participant cohort to be people 40-74 years of age who sought walk-in fingertip HbA<sub>1c</sub> testing at SMOs on the premises of community pharmacies. Costs and outcomes were discounted at a rate of 3%. The cost-effectiveness was analyzed from a societal perspective. The incremental cost per individual for those 40-74 years of age was estimated to be -527 U.S. dollars (USD) (-52,722 Japanese yen [JPY]) for HbA<sub>1c</sub> testing at SMOs compared with the status quo. Incremental effectiveness was estimated to be 0.0203 QALYs for HbA<sub>1c</sub> testing at SMOs compared with the status quo. Therefore, this cost-effectiveness analysis showed that compared with the status quo, HbA<sub>1c</sub> testing at SMOs was more effective and had lower cost for the population studied. We consider our results to be robust because most simulations were under the threshold of USD 50,000 (JPY 5,000,000) per QALYs gained, by sensitivity analysis. These results will be useful to managers of pharmacies or other health institutions and/or policy makers in local government.
Medical subject headings
- Diabetes Mellitus, Type 2
- Glycated Hemoglobin
- Mass Screening
- Pharmacies